Intestinal Microflora in Lung Cancer After Chemotherapy
NCT ID: NCT02771470
Last Updated: 2017-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
41 participants
INTERVENTIONAL
2014-09-30
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gut Microbiota and Cancer Immunotherapy Response
NCT04682327
Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC
NCT06613308
The Role of Microbiota on the Development of Lung Cancer
NCT03454685
The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients
NCT06428422
Exploratory Study of the Microbiome of Upper Gastrointestinal in the Pathogenesis of Multiple Primary Lung Cancer
NCT06973499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic
Microbial composition using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
Probiotics
Microbial composition using probiotic
Placebo
Microbiota modulation using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
placebo
Microbiota modulation using placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotics
Microbial composition using probiotic
placebo
Microbiota modulation using placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Other malignancy
* History of abdominal surgery
* Pregnant or breast-feeding (for females)
* Impaired liver or renal function
* Diabetes, thyroid disorder, coagulopathy or bleeding disorders, mental disorder
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanqing Li
Vice president of Qilu Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yanqing Li, MD.PhD.
Role: STUDY_CHAIR
Qilu Hospital, Shandong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Gastroenterology,Qilu Hospital,Shandong University
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014SDU-QILU-G06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.